Paolo Tarantino, MD

Paolo Tarantino, MD is an Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute and Harvard Medical School.

Articles

Key Messages From the Breast Cancer ADC Data Set and Closing Remarks

December 5th 2025

Experts discuss the transformative impact of antibody-drug conjugates (ADCs) in cancer treatment, emphasizing their growing role and the need for oncologists to adapt.

Treatment Duration, Maintenance Concepts, and Development of New ADC Targets in Breast

December 5th 2025

Experts discuss the need for better biomarker testing in ADC trials to ensure more patients benefit from targeted therapies.

Combination Approaches With ADCs and Emerging Clinical Strategies in Breast Cancer

December 5th 2025

Experts discuss the potential of maintenance strategies for antibody-drug conjugates in breast cancer, aiming to enhance patient outcomes and manage toxicity.

Rechallenge Strategies, Practice Logistics, and Patient Communication Regarding ADCs in Breast Cancer

December 5th 2025

Explore the innovative world of antibody-drug conjugates, revolutionizing cancer treatment with targeted therapies and reduced side effects.

Selecting HER2 or TROP2 Directed ADCs in HER2 Low and Hormone Receptor Positive Breast Cancer

December 5th 2025

Explore the evolving landscape of antibody-drug conjugates (ADCs) for breast cancer treatment and the strategic sequencing of therapies.

Supportive Care and Scheduling for Sacituzumab Govitecan in Clinical Practice in Breast Cancer

December 5th 2025

Explore the latest findings on Phase 3 trials for metastatic triple-negative breast cancer, highlighting treatment efficacy and toxicity profiles.

Clinical Impact of Datopotamab Deruxtecan in First Line Triple Negative Breast Cancer

December 5th 2025

A new drug shows promise in treating triple-negative breast cancer, significantly improving survival rates and offering hope for better treatment options.

CNS Recurrence and the Expanding Role of ADCs in Breast Cancer

December 5th 2025

Discover how novel antibody-drug conjugates effectively target brain metastases, offering hope for reducing CNS recurrences in cancer patients.

Clinical Significance of ADC in Breast Cancer: Updates Presented at ESMO 2025

December 5th 2025

Experts analyze groundbreaking antibody drug conjugate findings from ESMO 2025, highlighting their impact on breast cancer treatment strategies and patient care.

Dr Tarantino on the Efficacy of Neoadjuvant T-DXd/THP in High-Risk HER2+ Breast Cancer

November 5th 2025

Paolo Tarantino, MD, PhD, discussed the clinical implications of the DESTINY-Breast11 trial of T-DXd/THP in high-risk, HER2-positive early breast cancer.

Oncology Experts Dive Into Top Data From ESMO 2025

November 4th 2025

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Dr Tarantino on Clinical Implications of the neoCARHP Trial in HER2+ Breast Cancer

October 30th 2025

Paolo Tarantino, MD, PhD, discusses the clinical utility of data from the phase 3 neoCARHP trial in patients with HER2-positive early breast cancer.

Dr Tarantino on De-Escalated THP With/Without Carboplatin in HER2+ Breast Cancer

October 23rd 2025

Paolo Tarantino, MD, PhD, discusses key efficacy data with de-escalated THP with/without carboplatin in HER2-positive breast cancer.

Dr Tarantino on the Role of Genomic Testing in HER2+ Breast Cancer

October 16th 2025

Paolo Tarantino, MD, PhD, discusses the role of genomic testing for guiding treatment decisions for patients with HER2-positive breast cancer.

Dr Tarantino on the CompassHER2 pCR Trial of THP in HER2+ Breast Cancer

October 9th 2025

Paolo Tarantino, MD, PhD, discusses the design and background of the CompassHER2 pCR trial of THP in HER2-positive breast cancer.

Dr Tarantino on the Efficacy of Adjuvant THP in HER2+ Breast Cancer

September 8th 2025

Paolo Tarantino, MD, PhD, discusses the efficacy and safety of adjuvant THP in patients with stage II to IIIA HER2-positive breast cancer.

Dr Tarantino on the Role of ADCs in HER2+ Breast Cancer

July 11th 2025

Paolo Tarantino, MD, details the role of ADCs in HER2-positive breast cancer, along with unmet needs that persist.

Dr Tarantino on the Evolving Role of THP in HER2+ Metastatic Breast Cancer

June 19th 2025

Paolo Tarantino, MD, discusses the evolving role of trastuzumab plus pertuzumab and chemotherapy in HER2-positive breast cancer after DESTINY-Breast09.

T-DXd Plus Pertuzumab Could Redefine First-Line HER2+ Breast Cancer Management: With Paolo Tarantino, MD

June 11th 2025

Paolo Tarantino, MD, discusses key updates in HER2-positive breast cancer presented at the 2025 ASCO Annual Meeting

Dr Tarantino on Directions for Prospective Research in HER2+ Metastatic Breast Cancer

May 27th 2025

Paolo Tarantino, MD, PhD, discusses the need for prospective clinical trials to identify treatments for HER2+ breast cancer following progression on T-DXd.